Marinomed Biotech AG
4.00
EUR
0.00
(0.00%)
ISIN
ATMARINOMED6
Return %
Stock
S&P 500
1Y
-79.88
14.20
3Y
-89.96
81.12
5Y
-96.60
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Andreas Grassauer
- Full Time Employees
- 32
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Hovengasse 25 Korneuburg NI Austria 2100
- IPO Date
- Feb 1, 2019
- Website
- marinomed.com
- Similar Companies
- Business
- Marinomed Biotech AG, founded in 2006 and headquartered in Korneuburg, Austria, is a biopharmaceutical company specializing in the development of innovative therapeutic products for indications in virology and immunology. It operates primarily through its Virology and Immunology segments, offering a portfolio of over-the-counter (OTC) products including Carragelose-based nasal and throat sprays and lozenges for viral respiratory infections; allergen-blocking nasal sprays such as the Coldamaris Allergie launched for hay fever; moisturizing eye drops for treating dry eyes; and advanced pharmaceutical candidates like Budesolv for allergic rhinitis and Tacrosolv, currently in Phase II clinical trials for inflammatory eye diseases. The company also provides the proprietary Marinosolv® solubilization technology platform for enhancing drug solubility and bioavailability, which it offers to partners through its Solv4U business area. Marinomed maintains a lean business model focused on research and development, preclinical and clinical drug development, and outlicensing, while production and marketing are managed by partner pharmaceutical companies across multiple countries. Recent major developments at Marinomed include the successful launch of new allergen-blocking Carragelose products in Austria and Mexico, expanding its commercial footprint into Latin America’s second-largest pharmaceutical market and diversifying revenue sources beyond seasonal viral infections. The company established new distribution partnerships for Carragelose and Solv4U platforms, secured an international deal for Marinosolv with a $2 million down payment, and initiated clinical studies for moisturizing eye drops and allergen blockers. In 2024, Marinomed entered restructuring proceedings aiming to stabilize financially while continuing to grow its Carragelose portfolio and advance its Marinosolv assets. The company sold its Carragelose business unit to French CDMO Unither Pharmaceuticals in late 2024 as part of its strategic portfolio realignment. Marinomed operates internationally across Europe, Latin America, and other regions, leveraging partnerships for marketing and distribution while focusing on innovative drug development for viral and immune-related diseases. Overall, Marinomed Biotech AG combines proprietary drug technologies and OTC product offerings with strategic partnerships and pipeline assets to position itself as a specialized biopharmaceutical innovator headquartered in Austria. Its recent expansions and strategic transactions reflect a focus on broadening therapeutic reach, optimizing operational efficiency, and enhancing financial sustainability through collaborations and asset sales.